Daiichi Sankyo Co Ltd ASCO Transcript
Hello, colleagues. My name is Sunao Manabe, CEO of Daiichi Sankyo. Thank you for joining our briefing session focused on the key highlights of the data presented at ASCO of this year. Slide 4 show today's agenda. First, I will update our 5-year business plan for sustainable growth. And next, Ken Takeshita, our Global R&D Head, will present a summary of R&D progress and our updated R&D strategy. Finally, Mark Rutstein, our Head of Global Oncology Clinical Development, will show you the highlights of our presentation at ASCO this year.
Now let's move on to Slide 5. On This slide also highlight the position of our 5-year business plan for ensuring sustainable growth. Our 5-year business plan covers fiscal year 2021 through fiscal year 2025, is a plan designed to achieve our 2025 goal of being a global pharma innovator with a competitive advantage in oncology and to shift towards growth stage to realize our 2030 division.
Next, please. Slide 6 show the financial targets for fiscal year 2025 and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |